POSTMENOPAUSAL OSTEOPOROSIS

This study looks at whether adding the drug abaloparatide (Tymlos) to the standard treatment denosumab (Prolia) can improve bone density more than denosumab alone in postmenopausal women with osteoporosis. Seventy women who have already been on denosumab will either continue with…

This study looks at how teriparatide, a bone-building drug for severe osteoporosis, affects bone structure in postmenopausal women. Researchers will use a special scanner to see changes in bone thickness and tiny connecting rods at the wrist and ankle over 24 months. The goal is …

This study compares two FDA-approved medications, romosozumab and denosumab, for treating postmenopausal osteoporosis. Researchers will measure changes in hip bone density over 12 months in 50 women at high fracture risk. The goal is to see which drug works better to strengthen b…

This study tests an experimental drug called AGA2118 in postmenopausal women aged 55 to 80 who have low bone density but no history of fractures. The goal is to see if the drug can safely increase bone mineral density over 12 months compared to a placebo. About 379 women will par…

This early-stage study tests a new injectable drug called LYN101 in 44 people. First, healthy volunteers get a single dose to check safety. Then, postmenopausal women with low bone mass get multiple doses to see how the drug affects bone turnover markers. The main goal is safety,…

This study was designed to see if a special bone scanner (bone mineral analyser) could predict how well osteoporotic women would respond to a zoledronic acid infusion. The plan was to measure bone texture and density before and one year after treatment. However, the study was wit…

This study explores whether a new type of resistance exercise is practical and safe for people with low bone mass, including those with osteopenia, osteoporosis, or sarcopenia. Over two months, one group performs progressive muscle-strengthening exercises while a control group co…